p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor

Molecular Cell

Volumn 12, Issue 1, 2003, Pages 15-25

  Rocha, Sonia ^a   Campbell, Kirsteen J ^a   Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BCR ABL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CONTROLLED STUDY; DEFENSE MECHANISM; HUMAN; HUMAN CELL; ONCOGENE; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN FAMILY; PROTEIN FUNCTION; TRANSACTIVATION;

EID: 0043172452     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00223-5     Document Type: Article

References (47)

1. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2001;2177-2196.
2. Anderson L.A., Perkins N.D. Regulation of RelA (p65) function by the large subunit of replication factor C. Mol. Cell. Biol. 23:2003;721-732.
3. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107:2001;241-246.
4. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 18:1999;6910-6924.
5. Barnes P.J., Karin M. Mechanisms of disease - Nuclear Factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1997;1066-1071.
6. Chapman N.R., Webster G.A., Gillespie P.J., Wilson B.J., Crouch D.H., Perkins N.D. A novel form of the RelA Nuclear Factor κB subunit is induced by and forms a complex with the proto-oncogene c-Myc. Biochem. J. 366:2002;459-469.
7. Chen C.L., Edelstein L.C., Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20:2000;2687-2695.
8. Chiao P.J., Miyamoto S., Verma I.M. Autoregulation of IκB-α Activity. Proc. Natl. Acad. Sci. USA. 91:1994;28-32.
9. Cliby W.A., Lewis K.A., Lilly K.K., Kaufmann S.H. S phase and G(2) arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277:2002;1599-1606.
10. Eymin B., Karayan L., Seite P., Brambilla C., Brambilla E., Larsen C.J., Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene. 20:2001;1033-1041.
11. Fatyol K., Szalay A.A. The p14(ARF) tumor suppressor protein facilitates nucleolar sequestration of Hypoxia-Inducible Factor-1 α (HIF-1 α) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 276:2001;28421-28429.
12. Garg A., Aggarwal B.B. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia. 16:2002;1053-1068.
13. Hall-Jackson C.A., Cross D.A.E., Morrice N., Smythe C. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene. 18:1999;6707-6713.
14. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
15. Hoppeseyler F., Butz K. Repression of endogenous p53 transactivation function in Hela cervical-carcinoma cells by human papillomavirus type-16 e6, human Mdm-2, and mutant p53. J. Virol. 67:1993;3111-3117.
16. Jo H., Zhang R., Zhang H., McKinsey T.A., Shao J., Beauchamp R.D., Ballard D.W., Liang P. NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 19:2000;841-849.
17. Kabarowski J.H.S., Allen P.B., Wiedemann L.M. A temperature-sensitive p210 Bcr-Abl mutant defines the primary consequences of Bcr-Abl tyrosine kinase expression in growth-factor dependent cells. EMBO J. 13:1994;5887-5895.
18. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination. the control of NF-κB activity Annu. Rev. Immunol. 18:2000;621-623.
19. Kessis T.D., Slebos R.J., Nelson W.G., Kastan M.B., Plunkett B.S., Han S.M., Lorincz A.T., Hedrick L., Cho K.R. Human papillomavirus-16 E6 expression disrupts the p53-mediated cellular-response to DNA damage. Proc. Natl. Acad. Sci. USA. 90:1993;3988-3992.
20. Kuo M., Duncavage E.J., Mathew R., den Besten W., Pei D., Naeve D., Yamamoto T., Cheng C., Sherr C.J., Roussel M.F. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 63:2003;1046-1053.
21. Lebail O., Schmidtullrich R., Israel A. Promoter analysis of the gene encoding the IκB-α/Mad3 inhibitor of NF-κB - positive regulation by members of the Rel/NF-κB family. EMBO J. 12:1993;5043-5049.
22. Llanos S., Clark P.A., Rowe J., Peters G. Stabilization of p53 by p14(ARF) without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 3:2001;445-452.
23. Mason S.L., Loughran O., La Thangue N.B. p14(ARF) regulates E2F activity. Oncogene. 21:2002;4220-4230.
24. Mayo M.W., Wang C.Y., Cogswell P.C., Rogers-Graham K.S., Lowe S.W., Der C.J., Baldwin A.S. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science. 278:1997;1812-1815.
25. Michael D., Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12:2002;53-59.
26. Mosialos G. The role of Rel/NF-κB proteins in viral oncogenesis and the regulation of viral transcription. Semin. Cancer Biol. 8:1997;121-129.
27. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:1999;6853-6866.
28. Perkins N.D. The Rel/NF-κB family. friend and foe Trends Biochem. Sci. 25:2000;434-440.
29. Ravi R., Mookerjee B., van Hensbergen Y., Bedi G.C., Giordano A., El-Deiry W.S., Fuchs E.J., Bedi A. p53-mediated repression of Nuclear Factor-κB RelA via the transcriptional integrator p300. Cancer Res. 58:1998;4531-4536.
30. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 18:1999;6938-6947.
31. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:1998;968-981.
32. Rocha S., Soengas M.S., Lowe S.W., Glanzmann C., Fabbro D., Winterhalter K., Bodis S., Pruschy M. Protein kinase C inhibitor and irradiation-induced apoptosis. relevance of the cytochrome c-mediated caspase-9 death pathway Cell Growth Differ. 11:2000;491-499.
33. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-κB in p53-mediated programmed cell death. Nature. 404:2000;892-897.
34. Saccani S., Pantano S., Natoli G. Two waves of Nuclear Factor κB recruitment to target promoters. J. Exp. Med. 193:2001;1351-1359.
35. Sakurai H., Chiba H., Miyoshi H., Sugita T., Toriumi W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 274:1999;30353-30356.
36. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., Abraham R.T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59:1999;4375-4382.
37. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:2001;731-737.
38. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:1998;5001-5014.
39. Sugimoto M., Kou M., Roussel M.F., Sherr C.J. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell. 11:2003;415-424.
40. Tergaonkar V., Pando M., Vafa O., Wahl G., Verma I. p53 stabilization is decreased upon NFκB activation. a role for NFκB in acquisition of resistance to chemotherapy Cancer Cell. 1:2002;493-503.
41. Vermeulen L., De Wilde G., Notebaert S., Vanden Berghe W., Haegeman G. Regulation of the transcriptional activity of the Nuclear Factor-κB p65 subunit. Biochem. Pharmacol. 64:2002;963-970.
42. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta. 1602:2002;47-59.
43. Wadgaonkar R., Phelps K.M., Haque Z., Williams A.J., Silverman E.S., Collins T. CREB-binding protein is a nuclear integrator of Nuclear Factor-κB and p53 signaling. J. Biol. Chem. 274:1999;1879-1882.
44. Wang D., Baldwin A.S. Activation of nuclear factor-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273:1998;29411-29416.
45. Webster G.A., Perkins N.D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19:1999;3485-3495.
46. Wilson J., Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 12:2002;113-120.
47. Ziv Y., BarShira A., Pecker I., Russell P., Jorgensen T.J., Tsarfati I., Shiloh Y. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene. 15:1997;159-167.